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Summary
Benign neurofibromas and malignant peripheral nerve sheath tumors are serious complications of neurofibromatosis type
1. The epidermal growth factor receptor is not expressed by normal Schwann cells, yet is overexpressed in subpopulations
of Nf1 mutant Schwann cells. We evaluated the role of EGFR in Schwann cell tumorigenesis. Expression of EGFR in
transgenic mouse Schwann cells elicited features of neurofibromas: Schwann cell hyperplasia, excess collagen, mast cell
accumulation, and progressive dissociation of non-myelin-forming Schwann cells from axons. Mating EGFR transgenic
mice to Nf1 hemizygotes did not enhance this phenotype. Genetic reduction of EGFR in Nf1/;p53/ mice that develop
sarcomas significantly improved survival. Thus, gain- and loss-of-function experiments support the relevance of EGFR to
peripheral nerve tumor formation.
Introduction in utero by E13 due to cardiac defects (Brannan et al., 1994;
Gitler et al., 2003; Jacks et al., 1994). Targeted deletions at both
alleles in chimeric mice (Cichowski et al., 1999; Vogel et al.,Neurofibromatosis type 1 (NF1) is an autosomal dominant disor-
der, affecting approximately 1 in 3500 people (Huson, 1998; 1999) and most recently with the use of a conditional cre/lox
allele in Schwann cells in combination with a hemizygous Nf1Riccardi, 1992) The hallmark of NF1 is the development of up
to thousands of benign and slow-growing neurofibromas; more deficient environment (Gitler et al., 2003; Zhu et al., 2002) pro-
duced peripheral nerve pathology with features similar to plexi-aggressive peripheral nerve tumors, known asmalignant periph-
eral nerve sheath tumors (MPNSTs), develop in 5–10% of pa- form neurofibromas.
We have focused on identifying molecular alteration in cellstients (Evans et al., 2002; Friedman and Birch, 1997). The Nf1
gene on chromosome 17q11 encodes neurofibromin, a Ras- and tumors associated with Nf1mutation in cultures and animal
models. These studies have led to identification of aberrantGAP (Wallace et al., 1991; Xu et al., 1990). Mutations in both
Nf1 alleles in some neurofibroma Schwann cells and inMPNSTs expression of the epidermal growth factor receptor (EGFR;
ErbB1) in these tumor cells, and an EGFR-inducible protein,indicate that neurofibromin functions as a tumor suppressor
(Legius et al., 1993; Sawada et al., 1996; Serra et al., 1997). BLBP, that may regulate Schwann cell-axon interaction in these
models (DeClue et al., 2000; Li et al., 2002; Miller et al., 2003).Ras activation (Feldkamp et al., 1999; Sherman et al., 2000)
and invasiveness of neurofibroma Schwann cells (Sheela et al., Specifically, EGFR is expressed in primary MPNST, MPNST cell
lines, and some S100 Schwann cells in primary neurofibromas1990) from human tumors support the idea that Schwann cells
play a key role in neurofibroma formation. (DeClue et al., 2000). 23 of 24 cell lines derived from malignant
soft tissue sarcomas from Nf1:p53 compound heterozygousAnimal models of neurofibromatosis that accurately mimic
the peripheral nerve manifestations of the disease were chal- mice were also found to express EGFR (Li et al., 2002). EGFR
gene amplification is also observed in MPNSTs (Perry et al.,lenging to develop. In Nf1 knockout mice, no peripheral nerve
pathology exists in heterozygotes; offspring null at Nf1 die 2002). The identification of EGFR was of particular interest, as
S I G N I F I C A N C E
An ongoing debate in neurofibromatosis research is whether Nf1 mutant Schwann cells need cooperation from mutant surrounding
cells to drive neurofibroma formation. This paper shows that EGFR expression in Schwann cells not only produces a tumor-like
phenotype in Schwann cells, but also drives mast cell accumulation and fibrosis typical of human neurofibromas, without a mutant
environment. The work defines a model of early neurofibroma formation. In contrast to EGFR mutant brain tumor models, in the
peripheral nerve, a wild-type EGFR allele drives tumorigenesis. This work supports possible clinical utility of EGFR antagonists in NF1.
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Figure 1. Human EGFR protein is expressed in
CNPase-hEGFR transgenic mice
A: Western immunoblot of immunoprecipitates
from brain lysates demonstrating protein expres-
sion of hEGFR in two transgenic founder lines.
Positive control: RPMC cell line (human mela-
noma) known to express EGFR and ErbB2.
B: Sciatic nerve expression of hEGFR confirmed
with specimen 345–10, and demonstration of ac-
tive phosphorylated EGFR seen in spinal cord ly-
sate of specimen 442–10, after immunoprecipi-
tation. Positive control: RPMC cells stimulated
with EGF.
C: Demonstration of lack of heterodimer forma-
tion between hEGFR and ErbB2: lysates were im-
munoprecipitated with anti-hEGFR and blots
probed for ErbB2. No band noted in specimen
345–10, as compared to positive control RPMC
cells, which do exhibit heterodimer formation.
D: Immunohistochemistry of saphenous nerve
demonstrating cell-specific hEGFR expression
with positive Schwann cell sheath staining and
lack of axonal staining.
E and F: Low magnification saphenous nerve
staining for hEGFR in transgenic specimen (E) is
compared to lack of staining in wild-type speci-
men (F).
it is overexpressed or expressed as an active mutant in gliomas with only trace expression in non-nervous tissues (Figure 1A).
and in breast, endometrial, ovarian, colon, and cervical cancers We also detected hEGFR in sciatic nerve lysates from transgenic
(Yarden, 2001). Normal Schwann cells respond to products of but not wild-type mice (Figure 1B, left).
the neuregulin-1 gene, called neuregulins (Garratt et al., 2000; Ligand binding to the EGFR causes receptor autophosphor-
Levi et al., 1995; Morrissey et al., 1995). These are ligands for ylation, which leads to receptor activation as docking sites are
the receptor tyrosine kinases ErbB3 and ErbB4, which bear created for signaling proteins (Prenzel et al., 2001). To test if
homology to EGFR (Prenzel et al., 2001). Wild-type Schwann expressed hEGFR in the transgenicmice is activated,we probed
cells express the non-ligand-binding kinase ErbB2 and ErbB3, Western blots of sciatic nerve lysates precipitated with anti-
but not EGFR (DeClue et al., 2000; Levi et al., 1995). Based on human EGFR antibodies with an anti-phospho-EGFR antibody
these studies, we hypothesized that Schwann cell expression (Santa Cruz Biotech, Santa Cruz, California). Sciatic nerve ly-
of EGFR might be important in neurofibroma and/or MPNST sates fromCNP-hEGFRmice contained phosphorylated hEGFR
development, and tested this idea by developing a transgenic (Figure 1B, right), while lysates fromwild-type nerves did not (not
mouse strain expressing wild-type EGFR under control of a shown). Consistent with a low level of phosphorylated EGFR, we
Schwann cell promoter. We also show that genetic decrease found no detectable changes in Ras-GTP or AKT-phosphoryla-
of EGFR in a mouse model system of neurofibromatosis-related tion in Schwann cells from the mutant nerves as compared to
malignancy reduces tumorigenesis. wild-type cells (data not shown).
Ligand binding to EGFR can induce homodimerization or
Results heterodimerization with ErbB2 or ErbB4 (Murali et al., 1996;
Prenzel et al., 2001). Receptor dimerization is necessary for
hEGFR expression, dimerization, and activation
receptor activation. Schwann cells do not express ErbB4. Wein transgenic mice
tested if hEGFR/ErbB2 dimers are present in nerves from trans-To test the role of EGFR in neurofibroma formation, we devel-
genic mice. HEGFR formed no detectable heterodimers withoped transgenic mice in which the 23-cyclic nucleotide
ErbB2 in nerve lysates, although we easily detected dimers in3-phosphodiesterase (CNP) promoter, specific for Schwann
lysates from control RPMC cells (Figure 1C). Thus, hEGFR likelycells in peripheral nerve (Chandross et al., 1999; Gravel et al.,
exists as homodimers in CNP-hEGFR nerve. EGFR depends1998; Tsukada and Kurihara, 1992; Weissbarth et al., 1981),
on ligands for homodimerization and activation (Prenzel et al.,drives expression of human EGFR. We raised and bred four
2001). It is known that hEGFR transfected into mouse cellsfounder mice, and confirmed presence of the hEGFR transgene
signals appropriately when stimulated by ligand (Velu et al.,in two lines, designated CNP-hEGFR #10 and #46. Transgene
1987). We analyzed expression of EGFR ligands in wild-typeintegration effects are unlikely, as two independent lines of mice
and CNP-hEGFR sciatic nerves by quantitative real-time PCRdemonstrated pathology described below. We confirmed
(QRT-PCR). We detected betacellulin, HB-EGF, and TGF- inhEGFR protein expression with monoclonal anti-human EGFR
wild-type and CNP-hEGFR nerves at approximately equivalentantibody to probe Western blots after immunoprecipitation with
levels. No message was detected for EGF, epiregulin, or amphi-a polyclonal anti-EGFR antibody (Figure 1A). We detected ro-
regulin (Table 1). Schwann cells purified and expanded in culturebust hEGFR expression using the same method in brain and
spinal cord, where CNP drives expression in oligodendrocytes, expressed betacellulin and amphiregulin, confirming that pe-
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Table 1. mRNAs encoding EGFR ligands are present in adult peripheral nerve and cultured Schwann cells
A: Ligands
AR BTC EGF EPIREG HBEGF TGF-
WT nerve      
EGFR nerve      
MSC      
B: Quantification of ligands present in nerve
BTC BTC avg Ct GAPDH avg Ct Ct Ct Fold change
W/T 31.94  0.02 25.46  0.49 6.48  0.49 0.00  0.49 1 (0.71–1.41)
EGFR 27.90  0.02 27.76  0.15 5.14  0.15 1.34  0.15 2.53 (2.28–2.81)
HBEGF HBEGF avg Ct GAPDH avg Ct Ct Ct Fold change
W/T 31.42  0.05 27.61  0.50 3.81  0.50 0.00  0.60 1 (0.71–1.41)
EGFR 33.20  0.23 30.35  0.15 2.85  0.27 0.96  0.27 1.94 (1.61–2.35)
TGF- TGF- avg Ct GAPDH avg Ct Ct Ct Fold change
W/T 29.00  0.19 27.61  0.50 1.39  0.53 0.00  0.53 1 (0.69–1.44)
EGFR 31.00  0.23 30.35  0.15 0.65  0.27 0.74  0.27 1.67 (1.39–2.01)
A: Presence of EGFR ligand mRNA as detected by real-time PCR.
B: Quantification of ligands present in nerve. WT, wild-type; MSC, mouse Schwann cells; AR, amphiregulin; BTC, betacellulin; EGF, epidermal growth factor;
EPREG, epiregulin; HBEGF, heparin-binding epidermal growth factor; TGF-, transforming growth factor .
ripheral glia make EGFR ligands (Table 1). The data are consis-
tent with locally available ligands activating hEGFR receptors.
The CNP promoter drives expression in Schwann cells in
peripheral nerve and oligodendrocytes in the central nervous
system (Gravel et al., 1998). We stained sections of mouse
nervous system for hEGFR using a species-specific anti-human
EGFR antibody. We detected no obvious defects in brain oligo-
dendrocytes, possibly due to unavailability of EGFR ligands in
the brain. There may also be little effect of isolated EGFR signal-
ing in oligodendrocytes even if ligands are available. In saphe-
nous nerve, we detected labeling of myelinating Schwann cell
sheaths and inter-axon endoneurium staining suggestive of
nonmyelinating Schwann cells (NMSC); perineurium was not
labeled (Figure 1D). We found no staining of wild-type nerve
(Figure 1F) as compared to the much larger hEGFR saphenous
nerve (Figure 1E). Levels of EGFR expression in Schwann cell
lysates were similar to, or less than, those in 3 Nf1;p53 cell lines
that express EGFR by Western blotting (data not shown).
Nerves of CNPase-EGFR mice are enlarged
Neurofibromas enlarge nerves in NF1 patients. Gross inspection
of intercostal nerves, sciatic nerves, cauda equina, and cutane-
ous nerve twigs indicated diffuse hypertrophy in all CNPase-
hEGFR transgenicmice (data not shown).Wegathered quantita-
tive data on nerve size in saphenous nerve. Saphenous nerves
are easily accessible in dissections and maintain a constant
diameter, without branches, over a lengthy segment. We mea-
sured nerve cross-sectional area (Figure 2A). We noted a sig-
nificant, up to 8-fold, increase in area of transgenic nerves in
comparison to wild-type nerves (p  0.001). Hypertrophy was
also noted in cranial nerves of transgenic mice (data not shown).
Figure 2. CNPase-hEGFR nerves are enlarged and hypercellularHypercellularity in CNPase-hEGFR nerves
The histological basis of the nerve hypertrophy in CNPase- A: Cross-sectional area of saphenous nerves plotted with respect to age
and distinguished by genotype. Significant enlargement of CNPase-hEGFRhEGFR mice is attributable at least in part to hypercellularity.
and CNPase-hEGFR, Nf1/ nerves compared to wild-type (p  0.001 andWe counted nuclei in hematoxylin-stained nerve cross-sections
p  0.008, respectively) is seen.and found them tobeincreased2- to 8-fold in hEGFRnerves (p
B: Nuclei counts from saphenous nerve cross-sections accomplished by
0.01, Figure 2B). In contrast, there was no significant change hematoxylin staining. CNPase-hEGFR nerves have significantly increased
in number of myelinated axons: wild-type saphenous nerves nuclei (p  0.01).
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positive nuclei. We found 0.4% TUNEL-positive nuclei in wild-
type nerves (Grinspan et al., 1996); numbers of positive nuclei
in transgenic mice were not significantly different (p  0.16,
Figure 3E). Thus, ongoing increases in cell proliferation or de-
creased cell death are not detectable in adult nerves. Cell num-
ber increases may therefore occur at low levels throughout the
life of the animal, and/or at earlier times (see below). Human
neurofibroma cells also show little proliferation and death
(Kourea et al., 1999).
Hyperplastic endoneurial cells in transgenic nerves might
be Schwann cells, fibroblasts, and/or perineurial cells; each
is present at variable levels in neurofibromas. Wild-type and
CNPase-hEGFR nerve cells associated with myelin sheaths
showed cytoplasmic S100-positive staining, as expected for
myelinating Schwann cells (Mata et al., 1990) (Figures 3A and
3C), and p75NGFR immunoreactivity characteristic of non-
myelin-forming Schwann cells (NMSCs) (Figures 3B and 3D).
Greater than 90% of nuclei unassociated with myelin sheaths
were surrounded by GFAP-positive cytoplasm, supporting a
NMSCphenotype (Jessen et al., 1990). Continuous basal lamina
characteristic of Schwann cells were present on 90% of cells
in the endoneurium of CNPase-hEGFR saphenous nerves in
electron micrographs (Figures 3G and 3H). Most endoneurial
cells are therefore Schwann cells; others may be fibroblasts or
perineurial cells.
Unmyelinated fiber bundles and nonmyelinating
Schwann cells in CNPase-hEGFR mice exhibit
marked alterations which worsen with time
We analyzed electron micrographs to define nerve pathology.
Normal 4-month-old saphenous nerve contains large axons sur-
rounded by single myelin-forming Schwann cells and groups
of smaller axons ensheathed together by individual NMSCs
(Figure 4B). The same age transgenic saphenous nerves were
abnormal (n  5) (Figures 4A, 4D, and 4E). NMSCs displayed
long aberrant processes which wrapped one or two, or no, small
axons. Collagen fibers filled the nerve matrix between large
myelinated axons and were frequently, errantly, “wrapped” by
Schwann cell processes (Figures 3H and 4E, inset). Notably,
Figure 3. Hypercellularity is attributable to Schwann cells many Schwann cells in neurofibromas lack contact with axons.
The increased size of CNPase-hEGFR nerves results fromA–D: Markers for Schwann cells: S100 staining of saphenous nerve cross-
sections in wild-type (A) and CNPase-hEGFR (C) mice, and p75 staining in an increase in the number of nerve Schwann cells (Figure 2B),
wild-type (B) and CNPase-hEGFR (CM #69) (D) mice. increased collagen, and increased myelin thickness. We mea-
E and F: Assessment of apoptosis rates by TUNEL staining (E) and BrdU uptake
sured myelin sheath thickness (n  100) and the distance be-(F) over 6 hr in saphenous nerve cross-sections showing no significant differ-
tween myelin sheaths (n  100) in electron micrographs fromence between wild-type and CNPase-hEGFR nerves.
G and H: Electron micrographs: presence of a basal lamina (small arrows) 3 wild-type and 3 CNPase-hEGFR saphenous nerves. Both pa-
around a nonmyelinating Schwann cell and its ensheathed axons (Ax) in rameters were increased (p 	 .0001; Wilcoxon nonparametric
wild-type nerve (G). Basal lamina is present around membrane processes test).
in a CNPase-hEGFR nerve (H), indicating Schwann cell origin.
We observed the nerve pathology worsen with time. We
examined saphenous nerves at 4 months of age (n  2) and
found that nerves had NMSCs with aberrant processes. Our
cohort studied by EM included 2-month-old (n  2), 4-month-harbored on average 465 large axons, while transgenic nerves
old (n  5), and 6-month-old (n  2) transgenic mice. Nervesaveraged 499 (n  3 each; p  0.32). Increased numbers of
progressively accumulated collagen and dysfunctional Schwannendoneurial cells in mutant nerves could result from increased
cells, and had increasing numbers of disrupted small axonalproliferation and/or decreased cell death. We analyzed entry
fiber bundles (Figures 4F–4H). These patterns of pathology sug-into S phase of endoneurial cells in mutant nerves by labeling
gest a degenerative neuropathy of small caliber axons.with BrdU. In wild-type adult nerves, we detected the expected
lowproliferation rate (0.4%) in 6 hr as previously reported (Brown
CNPase-hEGFR nerves exhibit increased mast cellandAsbury, 1981).While the absolute numbers of BrdU-positive
infiltration and fibrosisnuclei were higher in transgenic nerves, the ratio of positive
Neurofibromas contain more mast cells than normal nervenuclei to total nuclei was not significantly different (p  0.96)
(Figure 3F). We analyzed cell death as measured by TUNEL- (Johnson et al., 1990). We observed granule-laden mast cells in
68 CANCER CELL : JANUARY 2005
A R T I C L E
Figure 4. Ultrastructural studies show pathology
of CNPase-hEGFR nerves
A: Electron micrograph montage of CNPase-
hEGFR saphenous nerve.
B: In comparison, wild-type saphenous nerve at
the same magnification.
C: A normal nonmyelinating Schwann cell nu-
cleus with cell membrane wrapping of small ax-
ons in wild-type nerve.
D–H: A markedly dysmorphic nucleus in CNPase-
hEGFR nerve with membrane wrapping of a lim-
ited number of axons (D), and another example
(E) showing Schwann cell processes with no as-
sociation with any axons and pathologic wrap-
ping of collagen fibrils (inset). Pathology is seen
to progress with time in CNPase-hEGFR nerves
comparing a 2.5-month-old specimen (F) to a
4-month-old specimen (G) and to a 6-month-old
specimen (H).
electron micrographs of hEGFR nerves (Figure 5A) and toluidine fibrosis, we confirmed enhanced collagen deposition by tri-
chrome stain (Figures 5G and 5H).blue-stained saphenous cross-section (Figure 5B). We counted
mast cells in saphenous nerve cross-sections. Mast cell num-
bers were significantly increased in adult transgenic mouse CNPase-hEGFR;Nf1/ mice do not show evidence
nerves compared to the wild-type counterpart (p  0.004) (Fig- of worsening pathology
ure 5C). Many mast cells were degranulating. Mast cell chemo- Loss-of-function ofNf1 in Schwann cells cooperateswithNf1/
attractants BDNF, MCP-1, SCF, TGF-
1, and VEGF were each in other cells in one NF1 mouse model (Zhu et al., 2002). To
upregulated in mutant nerves as determined by QRT-PCR (Fig- examine if Nf1/ worsened the CNPase-hEGFR nerve pheno-
ure 5D), likely accounting for the additional mast cells. Schwann type, we bred CNPase-hEGFR mice with Nf1/ mice. Dis-
cell hyperplasia precedes mast cell accumulation. Compared section along the neuroaxis and peripheral nervous system of
to the adult mice, in 4-week-old mice, Schwann cell numbers double heterozygous mice revealed similar diffuse nerve en-
increased significantly in EGFR nerves (Figure 5E), while mast largement as in CNPase-hEGFR mice. Saphenous nerves of 4
double-heterozygousmice were significantly larger (p 0.0075)cell numbers did not (Figure 5F). As mast cell products induce
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Figure 5. Mast cells and fibrosis in CNPase-hEGFR
mouse nerves
A: Mast cell seen in CNPase-hEGFR saphenous
nerve on electron micrograph.
B: Toluidine blue staining of CNPase-hEGFR sa-
phenous nerve cross-section showing multiple
metachromatic mast cells (arrows).
C: Mast cell counts in saphenous nerves, com-
paring wild-type mice (/) to CNPase-hEGFR
mice (EG) to CNPase-hEGFR;Nf1/ mice (EG/
NF). CNPase-hEGFR and CNPase-hEGFR;Nf1/
nerves harbor significantly more mast cells (p 
0.004 and p 0.015, respectively) than wild-type
nerves.
D: Differential expression of mast cell chemoat-
tractants mRNA in adult hEGFR or wild-type
mouse nerves as detected by real-time PCR. *,
expressed only in hEGFR nerve.
E: Total nuclei are increased in 4-week-old mouse
sciatic hEGFR nerves (p 	 0.0001).
F:Mast cell counting from toluidine blue stained 4
weeks old mice saphenous nerve cross-sections.
G and H: Wild-type saphenous nerve cross-sec-
tion stained with Gamori’s trichrome (G) showing
relative paucity of collagen (green) as com-
pared to CNPase-hEGFR nerves at 6 months (H).
Bar in G and H  500 M.
compared to wild-type mice, but not significantly different (p  tumor lysates from this mouse with a polyclonal anti-EGFR anti-
body (Figure 6E). hEGFRwas enriched in the tumor, demonstra-0.41) fromnerves ofmicewhichwere only EGFR-positive (Figure
2A; triangles). ting transgene association. We analyzed six CNPase-EGFR/
Nf1/ mice. Nerve thickening was consistent, but no nerve
tumors were detected, and no consistent cause of death wasCNPase-hEGFR mice develop rare nerve tumors
found. These data suggest that EGFR expression can lead toWe aged 19 CNPase-hEGFR and 12 wild-type littermates until
peripheral nerve tumorigenesis, benign and malignant, but thatmoribund. 42% of EGFR mice and 50% of wild-type mice re-
frank tumor formation in this model is rare, even when mice aremained alive at 23 months. We observed nerve thickening in
hemizygous for Nf1 mutation.11 EGFR mice evaluated at autopsy, but found no consistent
cause of death. We observed a grossly enlarged spinal nerve
Diminshed EGFR signaling decreases mortalityroot in one mouse diagnosed as a neurofibroma (Figure 6A).
in the Nf1;p53 mouse tumor modelAnother mouse developed a nerve-associated spindle cell tu-
mor with muscle differentiation (Figure 6B). Desmin and S100 To determine whether EGFR expression is important for Nf1-
associated tumor formation, we mated Nf1/;p53/mice tostaining (Figures 6C and 6D) were positive, confirming a diagno-
sis of triton tumor. We used an anti-human EGFR antibody to EGFRwa-2/ mice. As previously described, Nf1/;p53/ mice
develop sarcomas and brain tumors at as early as 15 weeks ofprobe Western blots after immunoprecipitation of brain and
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Figure 6. Tumors of CNPase-hEGFR mouse nerves
A: Enlarged spinal nerve root, diagnosed as a
neurofibroma, from CNPase-hEGFR mouse.
B–D: Rhabdomyosarcoma from CNPase-hEGFR
mouse (H&E). This was confirmed with S100 (C)
and desmin (CM #69) (D) staining.
E: Western immunoblot of immunoprecipitates of
brain and rhabdomyosarcoma lysates from this
mouse, demonstrating enriched hEGFR expres-
sion in the tumor. No expression of hEGFR was
seen in a lipoma from the same mouse.
Scale bar in A–D  1000 M.
age (Cichowski et al., 1999; Vogel et al., 1999; Reilly et al., some neurofibroma Schwann cells (DeClue et al., 2000; Li et
al., 2002), EGFR expression might have correlated with tumor2000). EGFRWa-2/ mice contain a point mutation in EGFR that
reduces receptor tyrosine kinase activity by 90%. Nf1/; formation, rather than being a causative event. Strikingly, our
data are consistent with a causative, and early, role for EGFRp53/ and Nf1/;p53/;EGFRwa-2/ littermates were followed
for six months. We compared mortality of the Nf1/;p53/ in progression to neurofibroma formation. EGFRoverexpression
mice (n  19) with the Nf1/;p53/;EGFRwa-2/ mice (n  17)
(Figure 7). Strikingly, reduced EGFR activity decreased tumor
formation time and mortality significantly (p 	 0.05). In this
study, 11 of 19 Nf1/;p53/ mice (57.9%) developed malig-
nant tumors and died by 26 weeks. In contrast, only 1 of 17
(5.9%) Nf1/;p53/;EGFRwa-2/ was dead at this time. This
mouse required sacrifice at 21 weeks due to a large periorbital
mass, pathologically diagnosed as a spindle cell tumor. Focal
S100 immunoreactivity and some mitotic activity allowed diag-
nosis of a GEM PNST, grade II (Stemmer-Rachamimov et al.,
2004). The remaining 16 mice remain healthy. Thus, decreased
levels of EGFR delay tumor formation and mortality in the
Nf1/;p53/ model.
Discussion
This study demonstrates the dramatic effect of expressing
EGFR in mouse Schwann cells. Peripheral and cranial nerves Figure 7. Improved survival of Nf1/;p53/;Egfrwa2/ mice
in CNP-hEGFR mice exhibit diffuse changes that parallel the
Mice were housed in a temperature- and humidity-controlled pathogen-
hallmarks of human cutaneous and plexiform neurofibromas. free viaticum and observed daily for evidence of illness or tumor formation.
These include increased endoneurial collagen matrix, dissocia- Mice were sacrificed if palpable tumor exceeded 1 cm in diameter or
interfered with feeding and grooming. Green, Nf1/;p53/ (n  19); red,tion of Schwann cells from axons, Schwann cell hypercellularity,
Nf1/;p53/;Egfrwa2/ (n  17); black, Egfrwa-2/ (n  20); and blue, wild-and mast cell accumulation. Changes were within the perineu-
type (WT) (n  21). The six-month survival of Nf1/;p53/;Egfrwa2/ mice was
rium, as is common in plexiform neurofibromas. While previous significantly different from Nf1/;p53/ mice in a Kaplan-Meier survival
analysis using SPSS software (p  .038).studies showed that EGFR is expressed in MPNST cells and
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is characteristic of, and contributes to, formation of many other tion documented. To our knowledge, to date, no other studies
have examined transgenic overexpression of tyrosine kinasehuman cancers. Therapeutic reagents that target EGFR are in
receptors in Schwann cells. However, the specificity of our resultclinical trials (Cunningham et al., 2004; Noble et al., 2004; Ran-
is suggested, in that Schwann cell transgenic overexpressionson et al., 2002; Yarden, 2001), and, based on our data, could
of GGF
3, a ligand for ErbB3, results in peripheral neuropathy,be considered as candidate therapeutics for NF1.
but not in the fibrosis and mast cell accumulation that we reportEGFR is not normally expressed in peripheral nerve Schwann
(Huijbregts et al., 2003). Prenatal treatment of mice with thecells. We used the CNP promoter to drive hEGFR expression
chemical carcinogen ENU (N-nitrosoethylurea) causes activa-in Schwann cells and specifically localized hEGFR to glial cells
tion of the ErbB2 tyrosine kinase in mouse Schwann cells (Bu-in endoneurium. It was possible that hEGFR heterodimerization
zard et al., 1999). Such exposure induces invasive Schwannwith Schwann cell-expressed ErbB2 might occur, but we failed
cell tumors with interdigitating Schwann cell processes, cystto detect such heterodimers in adult nerves. We demonstrated
formation, and parallel arrays of elongated neoplastic SchwannEGFR ligand expression in peripheral nerve, and in wild-type
cells in about 4% of mice from sensitive strains (Wechsler etSchwann cells. Based on these findings, it is likely that hEGFR
al., 1979); C57Bl/6 mice, such as those in our study, are highlyexpressed in Schwann cells homodimerize upon ligand stimula-
resistant. Carcinogen-induced mouse nerve tumors and growthtion, and become activated. Indeed, we detected phosphoryla-
factor overexpression result in nerve pathologies very differenttion of hEGFR in nerves.
from those in the EGFR transgenic mice. Together with ourThis new model provided the opportunity to study early
study, these data strongly support a key role for tyrosine kinasestages in neurofibroma formation, as pathology worsened with
pathways in regulation of non-myelin-forming Schwann cells inage and proximally to distally. Electron microscopy showed that
peripheral nerve.abnormal axon-glial interactions were present by 2 months of
To better understand the relevance of EGFR expression toage. Schwann cells wrapped progressively fewer axons, and
malignant tumor formation, we mated Nf1/;p53/ mice toultimately dissociated from axons and wrapped collagen fibrils.
EGFRwa-2/ mice. In a mouse model of colon cancer, the wa-2Effects of hEGFR expression were significantly greater on non-
mouse decreased adenoma number and prolonged survivalmyelinating Schwann cells than on those associated with my-
(Roberts et al., 2002; Sibilia et al., 2000). In this study, reductionelin, even though both Schwann cell types expressed hEGFR.
in EGFR expression in Nf1/;p53/;EGFRwa-2/ mice de-This is consistent with enhanced sensitivity of the nonmyelinat-
creased tumor formation and mortality significantly. This dataing Schwann cell to perturbed tyrosine kinase signaling down-
supports a crucial role for EGFR downstream of Nf1 signaling.stream of hEGFR, driving abnormal neuron-glial interactions.
MPNST formation is rare in the CNPase-EGFR-expressing miceEmphasizing a role for critical levels of tyrosine signaling in axon-
(shown here), as it is after chemical carcinogen exposure, affect-
glial interactions, Chen et al. (2003) showed that expression of
ing only 0.05% of sensitive mice (Wechsler et al., 1979). It is
a dominant negative ErbB4 receptor signaling in adult nonmy- likely that additional genetic events are necessary for frequent
elinating Schwann cells causes progressive sensory loss with malignancy in the CNPase-hEGFR model. Other tyrosine ki-
disruption of nonmyelinating Schwann cell bundles. Loss of the nases are expressed in human MPNST (Badache et al., 1998)
adhesion molecule L1 might also be involved, as mice without and could contribute to tumor growth. In human, EGFR is ampli-
L1 also showdisrupted nonmyelinating axon-Schwann cell units fied in 26% of MPNST (Perry et al., 2002), so this receptor is
(Haney et al., 1999). Human neurofibromas preferentially arise likely to be relevant to human MPNST tumor formation as it is
from sensory nerves that contain mainly unmyelinated Schwann in the Nf1-driven tumor model studied here.
cells. Based on our results, many neurofibroma Schwann cells This study shows that EGFR expression in Schwann cells
free of axons may have been associated at one time with small results in nerve hyperplasia with occasional neurofibroma for-
axons. mation. To develop neurofibromas at a higher rate, or malignan-
Mast cell accumulation and fibrosis are characteristic fea- cies, it may be necessary to cross these mice to strains with
tures of human neurofibromas and of peripheral nerves in other mutations. Cre/lox mediated ablation of Nf1 in Schwann
hEGFR mice. Mast cells did not express hEGFR on Western cells resulted in nerve pathology similar to that observed here,
blotting or immunostaining of tissue sections (data not shown). but only when the mice were also hemizygous for Nf1 mutation
Perineurial cells, of mesodermal origin, were also negative for (Zhu et al., 2002). Our model does not require mast cells and/
transgene expression. Nonglial cells accounted for few of the or fibroblasts to be Nf1/, as crossing hEGFR to Nf1/ mice
cells in the hEGFR nerves. It is reasonable to postulate that did not increase nerve size or Schwann cell number. The similar
hEGFR signaling in Schwann cells stimulates production and phenotype of hEGFR nerves to nerves in mice and humans,
secretion of mast cell chemoattractants, and here we have con- with loss of function mutation at Nf1 (Cichowski et al., 1999;
firmed that mRNA encoding the mast cell chemoattractants Vogel et al., 1999; Zhu et al., 2002), suggests that when loss
BNDF, MCP-1, SCF, TGF
1, and VEGF are each upregulated ofNf1predisposesSchwann cells, or their progenitors, to upreg-
in mutant nerve; one or more may recruit mast cells to the nerve. ulate EGFR, neurofibroma formation ensues. This new model
Mast cells migrate to SCF secreted by Schwann cells (Yang et will allow testing of EGFR antagonists in vivo for their ability to
al., 2003). Mast cell degranulation stimulates collagen deposi- prevent the formation of tumorgenic phenotypes. This study
further validates EGFR as a potential target for therapeutic inter-tion by fibroblasts. Fibrosis is commonly linked to mast cell
vention in NF1 patients.degranulation (Krishnaswamy et al., 2001). Thus, Schwann cell
hEGFR expression could promote multicellular changes in pe-
Experimental proceduresripheral nerve.
It remains possible that Schwann cell overexpression of Generation of CNPase-hEGFR transgenic mice
tyrosine kinase receptors in addition to EGFR could drive the We subcloned the 23-cyclic nucleotide 3-phosphodiesterase (CNP) pro-
moter (Chandross et al., 1999) into a Bluescript (Stratagene, La Jolla, CA)Schwann cell hyperplasia with fibrosis and mast cell accumula-
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backbone. We inserted the human EGFR cDNA (Velu et al., 1987) into SstII CCACCTC-3; product size, 300 bp), betacellulin (BTC; sense, 5-GGAACC
TGAGGACTCATCCA-3 and antisense, 5-TCTAGGGGTGGTACCTGTGC-and XhoI sites in the newly created multiple cloning site downstream of
the promoter. We confirmed sequence integrity by DNA sequencing (UC 3; product size, 227 bp), epidermal growth factor (EGF; sense, 5-GAGAGG
TGCAGAAGGACCTG-3 and antisense, 5-CACCAATTGCTGGTGATTTG-sequencing core facility). We excised the promoter, EGFR cDNA, and SV40
polyadenylation signal with VspI and MluI, and injected it into C57BL/6-SJL 3; product size, 271 bp), epiregulin (EPREG; sense, 5-TTCAGATGGAA
GACGATCCC-3 and antisense, 5-CGCAACGTATTCTTTGCTCA-3; prod-hybrid mouse oocytes.
uct size, 206 bp), heparin binding EGF (HBEGF; sense, 5-ATAGCTTTGCGC
TGTGACCT-3 and antisense, 5-CACACTCTTTGGTCCCACCT-3; producthEGFR localization
size, 166 bp), and transforming growth factor-
 (TGF
; sense, 5-TGTGTGAWe prepared tissue extracts using 10 l buffer (1% triton X100, 50 mM Tris
TAAAGCTGCCTGC-3 and antisense, 5-CAACCCTTTGAGGTTCGTGT-3;[pH 7.4], 150 mM NaCl, 1 g/ml aprotinin, 1 g/ ml leupeptin, 1 g/ml
product size, 100 bp). Cytokine primers are available on request. We pre-pepstatin, 1 mM PMSF)/mg tissue. We incubated lysates at 4C overnight
formed replicate reactions in an ABI Prism 7700 Sequence Detection Systemwith goat polyclonal anti-EGFR (Santa Cruz sc-03g; Santa Cruz, CA), and
Cycler according tomanufacturer’s instructions. We confirmed all PCR prod-then with protein A/G agarose beads (Santa Cruz). We subjected samples
ucts on 2% agarose gels. We calculated Ct values relative to GAPDHto SDS-PAGE on 4%–20% gradient gels, and probed blots with human
expression. We calculated the fold changes in CNP-hEGFR nerves com-specific mouse monoclonal anti-EGFR (Zymed; South San Francisco, CA)
pared to wild-type nerves using the equation 2 Ct, where Ct is the cycleor with anti-phosphorylated EGFR (Santa Cruz). We developed blots using
number at the chosen amplification threshold as determined by PE Biosys-an enhanced chemiluminescence kit (Amersham/Pharmacia; Piscataway, NJ).
tems software, CtCt(ligand)Ct(GAPDH), and CtCt(/)Ct(/) (K. Luvak,We studied EGFR dimer formation by immunoprecipitation using a hu-
PE ABI Sequence Detector User Bulletin 2).man-specific mouse monoclonal anti-EGFR (Upstate Biotech #05-101, Lake
Placid, NY). We ran 8% SDS-PAGE gels and probed blots with anti-ErbB2
Mice and genotyping(Oncogene Research c-neu; Cambridge, MA) or anti-hEGFR (Zymed). We
Nf1/;p53/mice carry theNf1 and p53mutations in cis onmouse chromo-used the RPM-MC human melanoma cell line known to express ErbB2 and
some 11 (Vogel et al., 1999). Mice had been backcrossed six generationsEGFR as a positive control.
onto the C57Bl/6 background at the time of the experiment. The tumor
spectrum on this background has been described (Reilly et al., 2000). WeImmunohistochemistry and histology
obtained B6EiC3H-Egfrwa2 mice from the Jackson Laboratory and back-We sacrificed mice by perfusion fixation with 4% paraformaldehyde and
crossed them one generation into C57Bl/6. We established the lines of miceharvested sciatic and saphenous nerves. We embedded nerves in paraffin
segregating Nf1/;p53/;Egfrwa2/, Nf1/;p53/;/, Nf1/;p53/;and cut 6 m thick cross-sections; every fifth section was mounted to avoid
Egfrwa-2/, and Nf1/;p53/;/ by crossing Nf1/;p53/ with Egfrwa2/double counting. We analyzed sciatic nerve sections proximal to the sciatic
carriers. Mice were housed in a temperature- and humidity-controlled viati-bifurcation. We stained sections with hematoxylin for nuclear counts, tolu-
cum that was kept on a 12 hr dark/light cycle with free access to food andidine blue for mast cells, and Gamori’s trichrome for collagen.
water. The animal care and use committees of the University of CincinnatiWe stained paraffin sections using a human-specific mouse monoclonal
and the Cincinnati Children’s Hospital Research Foundation approved allanti-EGFR (Zymed). Sectionswere first blocked for one hour using the Zymed
animal use. We genotyped Nf1 and p53 alleles as reported (Vogel et al.,Histomouse kit.We used rabbit polyclonal anti-cowS100 (Dako, Carpenteria,
1999). We genotyped Egfrwa-2 by PCR amplifying a 170 bp region (primers: 5-CA) and anti p75 (Chemicon, Teincula, CA). For fluorescence microscopy,
CCCAGAAAGGGATATGCG-3 and 5-GCAACCGTAGGGCATGAG-3) andwe used Alexa-488 fluorescent conjugated anti-rabbit secondary and coun-
digestingwith FokI to produce an uncut 170 bp or cut 75 and 95 bp fragmentsterstained with bisbenzamide (DAPI) to identify nuclei.
diagnostic for wild-type (wt) Egfr and Egfrwa2 alleles, respectively (Luetteke
et al., 1994).Schwann cell proliferation and apoptosis
We gave mice three intraperitoneal BrdU injections (0.05 mg/gm) at 2 hr
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